Get started
Author

Sabine Bender

Observed names: Bender, Sabine, S Bender, S. BENDER, S. Bender
Observed institutions: German Cancer Research Center, University of Zurich, University Hospital Heidelberg, University Hospital Zurich, Agouron Institute, University College London
OpenAlex ID: A5024678921
Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials
1999 · D. R. SHALINSKY, J. BREKKEN, et al. · Annals of the New York Academy of Sciences · 238
An MRAS, SHOC2, and SCRIB Complex Coordinates ERK Pathway Activation with Polarity and Tumorigenic Growth
2013 · Lucy C. Young, Nicole Hartig, et al. · Molecular Cell · 118
PDF
Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2016 · Ashish Sharma, Sabine Bender, et al. · Clinical Cancer Research · 42
The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
2017 · Katarzyna J. Nytko, Ivo Grgic, et al. · Oncotarget · 37
PDF
Combined Treatment Strategies for Microtubule Stabilizing Agent-Resistant Tumors
2015 · Angela Broggini-Tenzer, Ashish Sharma, et al. · JNCI Journal of the National Cancer Institute · 20
PDF
Perfusion CT radiomics as potential prognostic biomarker in head and neck squamous cell carcinoma
2019 · M. Bogowicz, S. Tanadini-Lang, et al. · Acta Oncologica · 17
PDF
The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes Non–Small Cell Lung Cancer for Radiotherapy
2021 · Fabienne Tschanz, Sabine Bender, et al. · Cancer Research Communications · 7
PDF
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study
2020 · Oliver Riesterer, Martin Pruschy, et al. · Radiotherapy and Oncology · 4
Fenretinide Acts as Potent Radiosensitizer for Treatment of Rhabdomyosarcoma Cells
2021 · Eva Brack, Sabine Bender, et al. · Frontiers in Oncology · 3
PDF
Secretome signature identifies ADAM17 as novel target for radiosensitization of non-small cell lung cancer
2016 · S. Bender, A. Sharma, et al. · European Journal of Cancer · 3
Supplementary Methods, Figure Legends and Table 1 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 6 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 2 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 5 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 1 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 2 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 3 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 5 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 4 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 6 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Data from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Data from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 4 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 1 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Suppl. Fig. 3 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
2023 · Ashish Sharma, Sabine Bender, et al.
Works count: 35
Citation count: 489
H-index: 7
I10-index: 6
Year
Topic
Type